Literature DB >> 118766

A long-term study of labetalol in general practice.

J Kane, I Gregg, M D Stephens.   

Abstract

1 Forty-one patients with mild to moderate hypertension have been treated with labetalol for up to 5 years. 2 Mean BP before treatment was 180/107 mm Hg, after 2--3 yr treatment was 136/81 mmHg and after 5 yr was 136/74 mmHg. 3 One patient developed a licheniform rash and two patients have died of myocardial infarction. No other side-effects, not already observed in a previously reported double-blind trial, have emerged.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 118766      PMCID： PMC1429750     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Acetohexamide: comparison with other sulfonylurea compounds in the treatment of diabetes mellitus.

Authors:  B R BOSHELL; A S WILENSKY; J C BARRETT; J V ALMON
Journal:  Clin Pharmacol Ther       Date:  1962 Nov-Dec       Impact factor: 6.875

2.  Antinuclear antibodies in patients receiving non-practolol beta-blockers.

Authors:  J D Wilson; J Y Bullock; D C Sutherland; C Main; K P O'Brien
Journal:  Br Med J       Date:  1978-01-07

3.  Bullous lichen planus caused by labetalol.

Authors:  R W Gange; E W Jones
Journal:  Br Med J       Date:  1978-04-01

4.  Double-blind trial of labetalol.

Authors:  J Kane; I Gregg; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

5.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Does labetalol increase excretion of urinary catecholamines?

Authors:  C A Hamilton; D H Jones; H J Dargie; J L Reid
Journal:  Br Med J       Date:  1978-09-16

7.  Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction.

Authors:  I A Mackie; D V Seal; J M Pescod
Journal:  Br J Ophthalmol       Date:  1977-05       Impact factor: 4.638

8.  Controlled comparison of labetalol and propranolol in the management of severe hypertension.

Authors:  D J Pugsley; B K Armstrong; M A Nassim; L J Beilin
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Affinity of labetalol for ocular melanin.

Authors:  D Poynter; L E Martin; C Harrison; J Cook
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335
  9 in total
  7 in total

1.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.

Authors:  S Rasmussen; P E Nielsen
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

3.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  Labetalol in general practice: a review.

Authors:  J A Kane
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 6.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 7.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.